{"id":31936,"date":"2021-10-08T00:00:25","date_gmt":"2021-10-08T07:00:25","guid":{"rendered":"https:\/\/vermont.salk.edu\/?post_type=disclosure&p=31936"},"modified":"2021-10-30T21:11:54","modified_gmt":"2021-10-31T04:11:54","slug":"salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy","status":"publish","type":"disclosure","link":"https:\/\/www.salk.edu\/de\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/","title":{"rendered":"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy"},"content":{"rendered":"

LA JOLLA\u2014The investigational Alzheimer\u2019s drug CMS121, developed and studied at Salk over the last fifteen years, has now moved into a phase 1 clinical trial to evaluate its safety in humans. Salk Research Professor Pamela Maher<\/a> and Bill Raschke of Virogenics, Inc., will receive $4.5 million over two years from the National Institute of Aging to support the trial, and they expect the first doses to be administered to healthy volunteers in early 2022. In mice, CMS121 reverses signs of aging in the brain and prevents the memory loss associated with Alzheimer\u2019s disease.<\/p>\n

\"Pamela
Pamela Maher
Klicken Sie hier<\/a> f\u00fcr ein hochaufl\u00f6sendes Bild.
Kredit: Salk Institut<\/figcaption><\/figure>\n

\u201cCMS121 is acting through a completely different pathway than most people have been looking at for Alzheimer\u2019s disease,\u201d says Maher, head of Salk\u2019s Cellular Neurobiology Laboratory. \u201cThis drug could actually make a difference for someone with Alzheimer\u2019s disease.\u201d<\/p>\n

In 2006, Maher and colleagues first discovered<\/a> that fisetin\u2014a natural chemical found in strawberries and other fruits and vegetables\u2014helped prevent cultured neurons from dying and boosted the memory of healthy mice. The team chemically altered the structure of fisetin and screened the new, related compounds for their ability to reverse the signs of aging in isolated brain cells. One of the synthesized fisetin derivatives\u2014CMS121\u2014was even more effective than fisetin<\/a> at slowing the degeneration of brain cells that occurs during aging.<\/p>\n

Since then, Maher\u2019s group has tested<\/a> the ability of CMS121 to treat Alzheimer\u2019s in a variety of mouse models of the disease. While many experimental Alzheimer\u2019s drugs aim to directly target the amyloid-\u03b2 protein that accumulates in the brains of people with the disease, CMS121 works by altering pathways related to inflammation and lipid synthesis.<\/p>\n

To move CMS121 toward commercial use, Maher partnered with San Diego-based biotech startup Virogenics, founded by Raschke, to carry out the extensive preclinical and Investigational New Drug (IND) studies required before compounds can be tested in humans. While many studies at this phase are funded by large pharmaceutical companies or rely on venture capital backing, Maher and Virogenics won a Small Business Technology Transfer Grant from the National Institute of Allergy and Infectious Diseases (NIAID) in 2013 to support their studies on CMS121. Now the phase 1 trial of CMS121 is being funded by the National Institute on Aging.<\/p>\n

\u201cIt\u2019s pretty amazing that we\u2019ve been able to see this drug from the lab all the way through to a phase 1 trial. It\u2019s also fairly unusual to do all of this entirely with support from the National Institutes of Health,\u201d says Maher. \u201cWe\u2019re very proud that we\u2019ve taken such a distinct approach.\u201d<\/p>\n

In the upcoming phase 1 trial, 56 healthy volunteers will take varying doses of CMS121 or a placebo in a randomized, double-blind study. Maher expects the data collection from the trial to be complete by fall 2022. \u201cWe hope that everything looks safe at that point and we can move on to a phase 2 trial,\u201d she says.<\/p>\n

The phase 1 clinical trial is being supported by the National Institute on Aging under Award Number R01AG074447.<\/p>","protected":false},"featured_media":31944,"template":"","faculty":[410],"disease-research":[127],"class_list":["post-31936","disclosure","type-disclosure","status-publish","has-post-thumbnail","hentry","faculty-pamela-maher","disease-research-alzheimers-disease"],"acf":[],"yoast_head":"\nSalk team launches phase 1 clinical trial for Alzheimer\u2019s therapy - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/de\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA\u2014The investigational Alzheimer\u2019s drug CMS121, developed and studied at Salk over the last fifteen years, has now moved into a phase 1 clinical trial to evaluate its safety in humans. Salk Research Professor Pamela Maher and Bill Raschke of Virogenics, Inc., will receive $4.5 million over two years from the National Institute of Aging to support the trial, and they expect the first doses to be administered to healthy volunteers in early 2022. In mice, CMS121 reverses signs of aging in the brain and prevents the memory loss associated with Alzheimer\u2019s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/de\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-31T04:11:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2021\/10\/Pam-Maher-767.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"767\" \/>\n\t<meta property=\"og:image:height\" content=\"767\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/\",\"name\":\"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Pam-Maher-767.jpg\",\"datePublished\":\"2021-10-08T07:00:25+00:00\",\"dateModified\":\"2021-10-31T04:11:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Pam-Maher-767.jpg\",\"contentUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Pam-Maher-767.jpg\",\"width\":767,\"height\":767,\"caption\":\"Pamela Maher\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/de\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/","og_locale":"de_DE","og_type":"article","og_title":"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy - Salk Institute for Biological Studies","og_description":"LA JOLLA\u2014The investigational Alzheimer\u2019s drug CMS121, developed and studied at Salk over the last fifteen years, has now moved into a phase 1 clinical trial to evaluate its safety in humans. Salk Research Professor Pamela Maher and Bill Raschke of Virogenics, Inc., will receive $4.5 million over two years from the National Institute of Aging to support the trial, and they expect the first doses to be administered to healthy volunteers in early 2022. In mice, CMS121 reverses signs of aging in the brain and prevents the memory loss associated with Alzheimer\u2019s disease.","og_url":"https:\/\/www.salk.edu\/de\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/","og_site_name":"Salk Institute for Biological Studies","article_modified_time":"2021-10-31T04:11:54+00:00","og_image":[{"width":767,"height":767,"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2021\/10\/Pam-Maher-767.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/","url":"https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/","name":"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2021\/10\/Pam-Maher-767.jpg","datePublished":"2021-10-08T07:00:25+00:00","dateModified":"2021-10-31T04:11:54+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/#primaryimage","url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2021\/10\/Pam-Maher-767.jpg","contentUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2021\/10\/Pam-Maher-767.jpg","width":767,"height":767,"caption":"Pamela Maher"},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/salk-team-launches-phase-i-clinical-trial-for-alzheimers-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"Salk team launches phase 1 clinical trial for Alzheimer\u2019s therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"Salk-Institut f\u00fcr biologische Studien","description":"Die Macht der Wissenschaft","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"Salk-Institut f\u00fcr biologische Studien","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"paper_url":"","journal_title":"","paper_author_list":"","doi":"","paper_title":"","subhead":"The compound being studied, CMS121, was first developed and studied at Salk","home_photo":"","listing_photo":"","legacy_boilerplate":[],"hide_boilerplate":[],"disable_date":false,"listing_excerpt":"","descriptive_blurb":"","has_journal_cover":false,"og_image_override":false,"gallery":false},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/31936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":6,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/31936\/revisions"}],"predecessor-version":[{"id":32047,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disclosure\/31936\/revisions\/32047"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/media\/31944"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/media?parent=31936"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/faculty?post=31936"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/de\/wp-json\/wp\/v2\/disease-research?post=31936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}